ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023
Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Secondary attack rates after mpox exposure in multiple settings during the 2022-2024 pandemic: a systematic review.BMC infectious diseases · 2026Pooled it
- Containment and response strategies for mpox outbreaks: a systematic review.BMC infectious diseases · 2025Pooled it
- Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.Emerging microbes & infections · 2024Pooled it
- Advancing Infectious Diseases Control in Africa: Lessons From the Mpox Re-emergence.Health science reports · 2025Article
- Review
- Harnessing community-based one health interventions implementation beyond Mpox outbreak management in Africa: insights and benefits.Infectious diseases of poverty · 2025Article
- Review
- Mpox containment strategies in China, 2022-2023: from preparedness to legal management.BMJ global health · 2025Review
- Is Southeast Asia and the Western Pacific ready for potential monkeypox virus outbreaks?The Lancet regional health. Western Pacific · 2025Review
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial.BMJ (Clinical research ed.) · 2024Article
- Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis.Health science reports · 2024Review
- Review
- Evaluation of pre-exposure vaccine effectiveness against mpox during the 2022-2023 mpox outbreak in the Madrid region (Spain): a test-negative design.BMJ public health · 2024Article
- Epidemiology, clinical presentation, and outcome of mpox: A study of 381 cases in Saudi Arabia.IJID regions · 2024Article
- Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study).Open forum infectious diseases · 2024Article
- The Current State and Progress of Mpox Vaccine Research.China CDC weekly · 2024Article
- Article
- JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: Challenges using real-world outbreak data.Vaccine · 2024Observational
- A Review of Mpox Outbreak and Public Health Response in Spain.Risk management and healthcare policy · 2024Review
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundAppropriate vaccination strategies have been key to controlling the outbreak of mpox outside endemic areas in 2022, yet few studies have provided information on mpox vaccine effectiveness (VE).AimTo assess VE after one dose of a third-generation smallpox vaccine against mpox when given as post-exposure prophylaxis (PEP) within 14 days.MethodsA survival analysis in a prospective cohort of close contacts of laboratory-confirmed mpox cases was conducted from the beginning of the outbreak in the region of Madrid in May 2022. The study included contacts of cases in this region diagnosed between 17 May and 15 August 2022. Follow up was up to 49 days. A multivariate proportional hazard model was used to evaluate VE in the presence of confounding and interaction.ResultsInformation was obtained from 484 close contacts, of which 230 were vaccinated within 14 days of exposure. Of the close contacts, 57 became ill during follow-up, eight vaccinated and 49 unvaccinated. The adjusted effectiveness of the vaccine was 88.8% (95% CI: 76.0-94.7). Among sexual contacts, VE was 93.6% (95% CI: 72.1-98.5) for non-cohabitants and 88.6% (95% CI: 66.1-96.2) for cohabitants.ConclusionPost-exposure prophylaxis of close contacts of mpox cases is an effective measure that can contribute to reducing the number of cases and eventually the symptoms of breakthrough infections. The continued use of PEP together with pre-exposure prophylaxis by vaccination and other population-targeted prevention measures are key factors in controlling an mpox outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.